SEC to review Nasdaq bitcoin options approval after CME challenge
The U.S. Securities and Exchange Commission has agreed to review its prior approval of Nasdaq's bitcoin options product following a formal challenge filed by CME Group, according to a report from CoinDesk. The SEC's decision to revisit the ruling opens a regulatory review process that could affect the competitive landscape for bitcoin derivatives trading in the United States.
CME Group, the world's largest derivatives exchange, submitted the challenge contesting the terms under which Nasdaq received regulatory clearance to offer bitcoin options. CME has long operated its own suite of bitcoin futures and options products and has been a dominant player in regulated crypto derivatives markets. The challenge represents a rare instance of one major exchange formally contesting another's regulatory approval before the SEC.
The review could have significant implications for institutional participants and market structure within the regulated bitcoin derivatives space. A reversal or modification of Nasdaq's approval could delay or alter the product's availability to investors, potentially redirecting trading volume and institutional interest toward existing platforms such as CME. Market participants will be closely watching whether the SEC imposes additional conditions or halts the product pending its findings.
Observers will be monitoring the SEC's timeline for completing the review, any formal responses from Nasdaq, and whether other exchanges or industry groups submit comments during the process. The outcome may also set a precedent for how competing exchanges can challenge rival approvals going forward.
Source: CoinDesk
